Remdesivir is a novel broad-spectrum antiviral therapeutic with activity against several viruses that cause emerging infectious diseases. The purpose of this study is to explore how commonly utilized antiretroviral therapy (tenofovir disoproxil fumarate/lamivudine [TDF/3TC] and atazanavir/ritonavir [ATV/r]) influence plasma and intracellular concentrations of remdesivir.

An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)

D'Avolio, Antonio;
2021-01-01

Abstract

Remdesivir is a novel broad-spectrum antiviral therapeutic with activity against several viruses that cause emerging infectious diseases. The purpose of this study is to explore how commonly utilized antiretroviral therapy (tenofovir disoproxil fumarate/lamivudine [TDF/3TC] and atazanavir/ritonavir [ATV/r]) influence plasma and intracellular concentrations of remdesivir.
2021
22
831
1
13
Atazanavir; COVID-19; Drug-drug interactions; Ebola; HIV; Lamivudine; Remdesivir; Ritonavir; Tenofovir
Walimbwa, Stephen I; Kaboggoza, Julian P; Waitt, Catriona; Byakika-Kibwika, Pauline; D'Avolio, Antonio; Lamorde, Mohammed
File in questo prodotto:
File Dimensione Formato  
13063_2021_Article_5752.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 682.9 kB
Formato Adobe PDF
682.9 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1821167
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact